Beta-blocker supplementation of standard drug treatment for schizophrenia

Schizophrenia Bulletin

Volumn 36, Issue 6, 2010, Pages 1079-1080

  Shek, Elena ^a   Bardhan, Sabyasachi ^a   Cheine, Maxim V ^b   Ahonen, Juha ^c   Wahlbeck, Kristian ^a  

^a Institute of Clinical Research India   (India)

^b Aurora Hospital   (Finland)

^c THL National Institute for Health and Welfare ^*

Author keywords

Adjunet; Beta blocker; Schizophrenia

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PLACEBO;

ARTICLE; CLINICAL TRIAL; DRUG EFFECT; HUMAN; HYPOTENSION; PRIORITY JOURNAL; RELAPSE; SCHIZOPHRENIA;

ADRENERGIC BETA-ANTAGONISTS; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; HYPOTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 78650078512     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbq089     Document Type: Article

References (1)

1. Shek E, Bardhan S, Cheine MV, Ahonen J, Wahlbeck K. Betablockersupplementation of standard drug treatment forschizophrenia. Cochrane Database Syst Rev. 2010; doi:10.1002/14651858.CD000234.